EDSAHIGH SIGNALFINANCIAL10-K

EDSA completed a major equity financing that dramatically improved its balance sheet, increasing cash from $1.0M to $10.8M while advancing paridiprubart to successful Phase 3 results in ARDS treatment.

The massive dilution (share count increased 140% from 3.5M to 8.3M shares) suggests investors paid a significant premium, likely driven by the breakthrough Phase 3 results showing paridiprubart met primary and secondary endpoints with statistical significance in ARDS patients. The company appears to have pivoted from COVID-19 applications to broader respiratory and chronic disease indications, positioning for multiple revenue streams.

Comparing 2025-12-12 vs 2024-12-13View on EDGAR →
FINANCIAL ANALYSIS

EDSA's financial position was transformed through what appears to be a substantial equity raise, with cash surging 980% to $10.8M and total stockholders' equity jumping 528% to $12.5M, while current liabilities decreased 41%. However, operating cash burn worsened by 50% to -$7.3M and net losses increased 16.5% to -$7.2M, indicating accelerated spending on R&D activities. The dramatic improvement in liquidity provides crucial runway for advancing clinical programs, but the significant share dilution will pressure per-share metrics going forward.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+980%
$1.0M$10.8M

Cash position surged 980% — strong cash generation or capital raise providing significant financial cushion.

Current Assets
Balance Sheet
+587.1%
$1.7M$11.5M

Current assets grew 587.1% — improving short-term liquidity or inventory/receivables build.

Stockholders Equity
Balance Sheet
+528.5%
$2.0M$12.5M

Equity base grew 528.5% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Assets
Balance Sheet
+254.8%
$3.8M$13.5M

Asset base grew 254.8% — expansion through organic growth, acquisitions, or capital deployment.

Inventory
Balance Sheet
+229.3%
$68K$224K

Inventory surged 229.3% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Accounts Receivable
Balance Sheet
+215.7%
$18K$56K

Receivables surged 215.7% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Operating Cash Flow
Cash Flow
-49.7%
-$4.9M-$7.3M

Operating cash flow fell 49.7% — earnings quality concerns; investigate working capital changes and non-cash items.

Current Liabilities
Balance Sheet
-41.2%
$1.8M$1.1M

Current liabilities reduced — improved short-term financial position and working capital health.

R&D Expense
P&L
+27.3%
$2.9M$3.7M

R&D investment increased 27.3% — signals commitment to future product development, though near-term margin impact.

Net Income
P&L
-16.5%
-$6.2M-$7.2M

Net income declined 16.5% — review whether driven by operations, interest costs, or non-recurring items.

LANGUAGE CHANGES
NEW — 2025-12-12
PRIOR — 2024-12-13
ADDED
As of December 12, 2025, the registrant had 8,333,823 common shares issued and outstanding.
Subject to regulatory approval, we anticipate initiating enrollment by midyear 2026.
In October 2025, we reported that paridiprubart met primary and secondary endpoints with statistical significance, providing clinically meaningful improvement in survival and recovery, in a truncated Phase 3 clinical study of hospitalized patients with Acute Respiratory Distress Syndrome ( ARDS ), a life-threatening form of respiratory failure.
government-funded platform study investigating three novel threat-agnostic HDTs in hospitalized patients with ARDS.
We are also pursuing additional uses for paridiprubart in chronic diseases.
+7 more — sign up free →
REMOVED
As of December 11, 2024, the registrant had 3,467,658 common shares issued and outstanding.
government-funded platform study investigating three novel threat-agnostic HDTs in hospitalized adult patients with Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure.
In addition to EB05, we are also preparing an investigational new drug application (IND) in the United States to conduct a future Phase 2 study for EB07 (paridiprubart) in patients with pulmonary fibrosis.
The 28-day death rate in the EB05 plus standard of care (SOC) arm was 7.7% versus 40% in the placebo + SOC arm in critically severe patients on ECMO therapy (extracorporeal membrane oxygenation) or Invasive Mechanical Ventilation (IMV) plus organ support with ARDS at baseline (p=0.04).
The Phase 2 study demonstrated that EB05 appears to be well-tolerated and consistent with the observed safety profile to date.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →